pegunigalsidase alfa sold brand name elfabrio enzyme replacement therapy treatment fabry recombinant human hydrolytic lysosomal neutral glycosphingolipidspecific common side effects infusionrelated reactions hypersensitivity pegunigalsidase alfa approved medical use european union united states may pegunigalsidase alfa indicated longterm enzyme replacement therapy aduls confirmed diagnosis fabry disease deficiency february committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product elfabrio intended treatment fabry applicant medicinal product chiesi farmaceutici elfabrio approved medical use european union may drug article relating gastrointestinal system stub help wikipedia expanding httpsenwikipediaorgwikipegunigalsidasealfa